Bovie Medical Corp. Announces Corporate Name Change to Apyx Medical Corp. & Plans to Transition Common Stock Listing to NASDA...
12 Décembre 2018 - 10:05PM
Business Wire
Bovie Medical Corporation (NYSE:BVX) (the “Company”), a
maker of medical devices and supplies and the developer of
J-Plasma®, a patented surgical product marketed and sold under the
Renuvion® Cosmetic Technology brand in the cosmetic surgery market,
today announced a corporate rebranding and company name change to
Apyx Medical Corporation effective January 1, 2019. The Company
also announced plans to move its stock exchange listing to the
NASDAQ Global Select Market (the “NASDAQ”) from the New York Stock
Exchange (the “NYSE”). The Company expects that its common stock
will commence trading on the NASDAQ Global Select Market on January
2, 2019, under a new ticker symbol – “APYX”.
“We are pleased to join the world’s most innovative and
growth-oriented companies listed on NASDAQ and are excited to
partner with NASDAQ to leverage trading liquidity, enhanced
visibility for issuers, leading technology and cost efficiencies,”
said Charlie Goodwin, President and Chief Executive Officer. “We
also announced a corporate rebranding and Company name change to
Apyx Medical Corporation which is the final milestone resulting
from the previously announced divestiture and sale of the Core
business segment and Bovie brand to Symmetry Surgical, Inc.”
Mr. Goodwin continued: “The new name and brand emphasizes the
Company’s goal to be the most innovative, customer and solution
focused company in the cosmetic surgery market and the broader
medical technology sector. Apyx Medical Corporation endeavors to
reshape the cosmetic surgery market by providing unique and
creative solutions for the ever-changing needs of our physician
customers and their patients.”
The Company will ring the NASDAQ Stock Market opening bell on
January 3, 2019, in Times Square, New York, NY. President and Chief
Executive Officer, Charlie Goodwin, and members of the Company’s
management team and Board of Directors will participate in the
opening bell ringing ceremony from 9:00 am to 9:30 am ET. A live
webcast will be available
at https://new.livestream.com/nasdaq/live.
About Bovie Medical
Corporation:
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma® (marketed and
sold under the Renuvion™ Cosmetic Technology brand in the cosmetic
surgery market), a patented plasma-based surgical product for
cutting, coagulation and ablation of soft tissue. J-Plasma
technology utilizes a helium ionization process to produce a
stable, focused beam of plasma that provides surgeons with greater
precision, and minimal invasiveness. The new J-Plasma
handpieces with Cool-Coag™ technology deliver the precision of
helium plasma energy, the power of traditional monopolar
coagulation and the efficiency of plasma beam coagulation -
enabling thin-layer ablation and dissection and fast coagulation
with a single instrument, minimizing instrument exchange and
allowing a surgeon to focus on their patient and their procedures.
With Cool-Coag technology, the new J-Plasma handpieces can deliver
three distinctly different energy modalities - further increasing
the utility and versatility of the system. The Company also
leverages its expertise through original equipment manufacturing
(OEM) agreements with other medical device manufacturers. For
further information about the Company and its products, please
refer to the Bovie Medical Corporation website
at www.boviemedical.com.
Cautionary Statement on Forward-Looking
Statements:
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
Forward-looking information is subject to certain risks, trends
and uncertainties that could cause actual results to differ
materially from those projected. Many of these factors are beyond
the Company’s ability to control or predict. Important factors that
may cause actual results to differ materially and that could impact
the Company and the statements contained in this release can be
found in the Company’s filings with the Securities and Exchange
Commission including the Company’s Report on Form 10-K for the year
ended December 31, 2017 and subsequent Form 10-Q filings. For
forward-looking statements in this release, the Company claims the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181212005829/en/
Investor Relations
Contact:Westwicke Partners on behalf of Bovie
Medical CorporationMike Piccinino,
CFA443-213-0500investor.relations@boviemed.com
Bovie (AMEX:BVX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Bovie (AMEX:BVX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024